首页> 外文期刊>The biochemical journal >Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy
【24h】

Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy

机译:结缔组织生长因子在糖尿病肾病发病机制中的作用

获取原文
获取外文期刊封面目录资料

摘要

pWe characterized a rabbit polyclonal antibody raised against human recombinant connective tissue growth factor (CTGF). The antibody recognised a higher molecular mass form (approx. 56kDa) of CTGF in mesangial cell lysates as well as the monomeric (36–38kDa) and lower molecular mass forms (& 30kDa) reported previously. Immunohistochemistry detected CTGF protein in glomeruli of kidneys of non-obese diabetic mice 14 days after the onset of diabetes, and this was prominent by 70 days. CTGF protein is also present in glomeruli of human patients with diabetic nephropathy. No CTGF was detected in either normal murine or human glomeruli. Transient transfection of a transformed human mesangial cell line with a CTGF–V5 epitope fusion protein markedly increased fibronectin and plasminogen activator inhibitor-1 synthesis in cultures maintained in normal glucose (4mM) conditions; a CTGF-antisense construct reduced the elevated synthesis of these proteins in high glucose (30mM) cultures. Culture of primary human mesangial cells for 14 days in high glucose, or in low glucose supplemented with recombinant CTGF or transforming growth factor β1, markedly increased CTGF mRNA levels and fibronectin synthesis. However, whilst co-culture with a CTGF-antisense oligonucleotide reduced the CTGF mRNA pool by greater than 90% in high glucose, it only partially reduced fibronectin mRNA levels and synthesis. A chick anti-CTGF neutralizing antibody had a similar effect on fibronectin synthesis. Thus both CTGF and CTGF-independent pathways mediate increased fibronectin synthesis in high glucose. Nevertheless CTGF expression in diabetic kidneys is likely to be a key event in the development of glomerulosclerosis by affecting both matrix synthesis and, potentially through plasminogen activator inhibitor-1, its turnover./p
机译:>我们鉴定了针对人重组结缔组织生长因子(CTGF)的兔多克隆抗体。该抗体识别肾小球膜细胞裂解物中CTGF的较高分子量形式(约56kDa),以及先前报道的单体(36-38kDa)和较低分子量形式(<30kDa)。免疫组化在糖尿病发作后14天在非肥胖糖尿病小鼠肾脏的肾小球中检测到CTGF蛋白,这一现象在70天时就很明显。 CTGF蛋白也存在于糖尿病肾病患者的肾小球中。在正常鼠或人肾小球中均未检测到CTGF。用正常生长在正常葡萄糖(4mM)条件下的培养物中,用CTGF-V5表位融合蛋白瞬时转染转化的人肾小球系膜细胞,可显着增加纤连蛋白和纤溶酶原激活物抑制剂1的合成。 CTGF反义构建体减少了在高葡萄糖(30mM)培养物中这些蛋白质合成的升高。在高葡萄糖或补充重组CTGF或转化生长因子β1的低葡萄糖条件下,原代人肾小球系膜细胞培养14天,可显着增加CTGF mRNA水平和纤连蛋白合成。但是,尽管与CTGF反义寡核苷酸共培养可在高葡萄糖条件下将CTGF mRNA池降低90%以上,但只能部分降低纤连蛋白mRNA水平和合成。雏鸡的抗CTGF中和抗体对纤连蛋白的合成具有类似的作用。因此,CTGF和独立于CTGF的途径在高葡萄糖中介导纤连蛋白合成增加。然而,糖尿病肾脏中CTGF的表达可能是肾小球硬化症发展的关键事件,因为它既影响基质合成,也可能通过纤溶酶原激活物抑制剂1影响其更新。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号